A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell- based vaccines

Human Gene Therapy

Volumn 10, Issue 12, 1999, Pages 1983-1991

  Borrello, Ivan ^a   Sotomayor, Eduardo M ^a   Cooke, Sara ^a   Levitsky, Hyam I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR CELL VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CULTURE MEDIUM; CYTOKINE RELEASE; GENE TRANSFER; GENETIC TRANSDUCTION; HLA SYSTEM; HUMAN; HUMAN CELL; IRRADIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; TUMOR IMMUNITY; VACCINATION; VACCINE PRODUCTION;

ANIMALS; CANCER VACCINES; CELL LINE; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0033543076     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017347     Document Type: Article

References (23)

1. BANCHEREAU, J., and STEINMAN, R.M. (1998). Dendritic cells and the control of immunity. Nature (London) 392, 245-252.
2. DRANOFF, G. (1998). The use of gene transfer in cancer immunotherapy. Forum (Geneva) 8, 357-364.
3. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOLL, D., and MULLIGAN, R.C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
4. DUNUSSI-JOANNOPOULOS, K., DRANOFF, G., WEINSTEIN, H.J., FERRARA, J.L.M., BIERER, B.E., and CROOP, J.M. (1998). Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 91, 222-230. [In Process Citation]
5. GOLUMBEK, P.T., AZHARI, R., JAFFEE, E.M., LEVITSKY, H.I., LAZENBY, A., LEONG, K., and PARDOLL, D.M. (1993). Controlled release, biodegradable cytokine depots: A new approach in cancer vaccine design. Cancer Res. 53, 5841-5844.
6. HUANG, A.Y., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994a). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
7. HUANG, A.Y., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994b). Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumor immune response. Ciba Found. Symp. 187, 229-240; discussion, 240-244.
8. HUNG, K., HAYASHI, R., LAFOND-WALKER, A., LOWENSTEIN, C., PARDOLL, D., and LEVITSKY, H. (1998). The central role of CD(+) T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368.
9. HURWITZ, A.A., YU, T.F., LEACH, D.R., and ALLISON, J.P. (1998). CTLA-4 blockade synergized with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. U.S.A. 95, 10067-10071.
10. INABA, K., INABA, M., ROMANI, N., AYA, H., DEGUCHI, M., IKEHARA, S., MURAMATSA, S., and STEINMAN, R.M. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with graulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702.
11. JAFFEE, E.M., LAZENBY, A., MEURER, J., MARSHALL, F., HAUDA, K.M., COUNTS, C., HURWITZ, H., SIMONS, J.W., LEVITSKY, H.I., and PARDOLL, D.M. (1995). Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J. Immunother. Emphasis Tumor Immunol. 18, 1-9.
12. JAFFEE, E.M., THOMAS, M.C., HUANG, A.Y., HAUDA, K.M., LEVITSKY, H.I., and PARDOLL, D.M. (1996). Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis Tumor Immunol. 19, 176-183.
13. LEVITSKY, H.I., LAZENBY, A., HAYASHI, R.J., and PARDOLL, D.M. (1994). In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression. J. Exp. Med. 179, 1215-1224.
14. LEVITSKY, H.I., MONTGOMERY, J., AHMADZADEH, M., STAVELEY, C.K., GHUARNIERI, F., LONGO, D.L., and KWAK, L.W. (1996). Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 156, 3858-3865.
15. MORRISON, L.A., LUKACHER, A.E., BRACIALE, V.L., FAN, D.P., and BRACIALE, T.J. (1986). Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J. Exp. Med. 163, 903-921.
16. PARDOLL, D.M. (1998). Cancer vaccines. Nature Med. 4, 525-531.
17. QIN, Z., NOFFZ, G., MOHAUPT, M., and BLANKENSTEIN, T. (1997). Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159, 770-776.
18. SANDA, M.G., AYYAGARI, S.R., JAFFEE, E.M., EPSTEIN, J.I., CLIFT, S.L., COHEN, L.K., DRANOFF, G., PARDOLL, D.M., MULLIGAN, R.C., and SIMONS, J.W. (1994). Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151, 622-628.
19. SIMONS, J.W., JAFFEE, E.M., WEBER, C.E., LEVITSKY, H.I., NELSON, W.O., CARDUCCI, M.A., LAZENBY, A.J., COHEN, L.K., FINN, C.C., CLIFT, S.M., HAUDA, K.M., BECK, L.A., LEIFERMAN, K.M., OWENS, A.H., JR., PIANTADOSI, S., DRANOFF, G., MULLIGAN, R.C., PARDOLL, D.M., and MARSHALL, F.F. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546.
20. SIMONS, J.W., MIKHAK, B., CHANG, J-F., DEMARZO, A.M., CARDUCCI, M.A., LIM, M., WEBER, C.E., BACCALA, A.A., GOEMANN, M.A., CLIFT, S.M., ANDO, D.G., et al. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of tumor cells engineered to secrete GM-CSF using ex-vivo gene transfer. Cancer Res. (in press).
21. SOIFFER, R., LYNCH, T., MIHM, M., JUNG, K., RHUDA, C., SCHMOLLINGER, J.C., HODI, F.S., LIEBSTER, L., LAM, P., MENTZER, S., SINGER, S., TANABE, K.K., COSIMI, A.B., DUDA, R., SOBER, A., BHAN, A., DALEY, J., NEUBERG, D., PARRY, G., ROKOVICH, J., RICHARDS, L., DRAYER, J., BERNS, A., CLIFT, S., DRANOFF, G., et al. (1998). Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 95, 13141-13146.
22. THOMAS, M.C., GRETEN, T.F., PARDOLL, D.M., and JAFFEE, E.M. (1998). Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum. Gene Ther. 9, 835-843.
23. TOES, R.E., BLOM, R.J., VAN DER VOORT, E., OFFRINGA, R., MELIEF, C.J., and KAST, W.M. (1996). Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 56, 3782-3787